$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

If both its BioN­Tech-part­nered Covid-19 vac­cine and in-house an­tivi­ral live up to their full promis­es, Pfiz­er may be sit­ting on a $100 bil­lion gold­mine in 2022.

That’s ac­cord­ing to SVB Leerink an­a­lyst Ge­of­frey Porges, who re­leased his lat­est fore­cast ear­ly Tues­day com­plete with a lengthy break­down of all the in­tri­cate fac­tors go­ing in­to his cal­cu­la­tion. Bot­tom line: uni­ver­sal boost­ing and pe­di­atric rec­om­men­da­tions will shore up glob­al Covid vac­cine sales to $59 bil­lion in 2021 and $48 bil­lion in 2022, or $107 bil­lion in cu­mu­la­tive sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.